Literature DB >> 28450131

Cerebral microbleeds, cognitive impairment, and MRI in patients with diabetes mellitus.

Hong Zhou1, Juan Yang1, Peihan Xie1, Yulan Dong1, Yong You2, Jincai Liu3.   

Abstract

Cerebral microbleeds (CMBs), a typical imaging manifestation marker of sporadic cerebral small vessel disease, play a critical role in vascular cognitive impairment, which is often accompanied by diabetes mellitus (DM). Hence, CMBs may, in part, be responsible for the occurrence and development of cognitive impairment in patients with diabetes. Novel magnetic resonance imaging (MRI) sequences, such as susceptibility-weighted imaging and T2*-weighted gradient-echo, have the capability of noninvasively revealing CMBs in the brain. Moreover, a correlation between CMBs and cognitive impairment in patients with diabetes has been suggested in applications of functional MRI (fMRI). Since pathological changes in the brain occur prior to observable decline in cognitive function, neuroimaging may help predict the progression of cognitive impairment in diabetic patients. In this article, we review the detection of CMBs using MRI in diabetic patients exhibiting cognitive impairment. Future studies should emphasize the development and establishment of a novel MRI protocol, including fMRI, for diabetic patients with cognitive impairment to detect CMBs. A reliable MRI protocol would also be helpful in understanding the pathological mechanisms of cognitive impairment in this important patient population.
Copyright © 2017. Published by Elsevier B.V.

Entities:  

Keywords:  Cerebral microbleeds; Cognitive impairment; Diabetes mellitus; Functional magnetic resonance imaging; Magnetic resonance imaging

Mesh:

Year:  2017        PMID: 28450131     DOI: 10.1016/j.cca.2017.04.019

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  7 in total

1.  Clinical and MRI features about two types of silent cerebral small-vessel disease in type-2 diabetes mellitus: a retrospective cross-sectional study in a tertiary hospital.

Authors:  Dan-Qiong Wang; Lei Wang; Xiao-Shuang Xia; Miao-Miao Wei; Xiao-Lin Tian; Liang-Fang Wang; Xin Li
Journal:  Quant Imaging Med Surg       Date:  2022-04

2.  Cerebral Small Vessel Disease is Associated with Mild Cognitive Impairment in Type 2 Diabetes Mellitus.

Authors:  Zhenjie Teng; Jing Feng; Ronghui Liu; Yanhong Dong; Huifang Chen; Jing Xu; Xin Jiang; Rui Li; Peiyuan Lv
Journal:  Diabetes Metab Syndr Obes       Date:  2022-07-02       Impact factor: 3.249

3.  Comparative efficacy and safety of traditional Chinese patent medicine for cognitive dysfunction in diabetic cognitive dysfunction: A protocol for systematic review and Bayesian network meta-analysis.

Authors:  Kai Wang; Zhenyuan Jiang; Xiaowen Yu; Yuze Shao; Hailiang Liu; Susu Wu; Linghui Kong; Zhonglin Wang
Journal:  Medicine (Baltimore)       Date:  2022-03-11       Impact factor: 1.817

4.  Assessment of cerebral microbleeds by susceptibility-weighted imaging at 3T in patients with end-stage organ failure.

Authors:  Gianvincenzo Sparacia; Roberto Cannella; Vincenzina Lo Re; Angelo Gambino; Giuseppe Mamone; Roberto Miraglia
Journal:  Radiol Med       Date:  2018-02-17       Impact factor: 3.469

Review 5.  The relationship between diabetes-related cognitive dysfunction and leukoaraiosis.

Authors:  Chun-Lan Yuan; Ran Yi; Qi Dong; Li-Fen Yao; Bin Liu
Journal:  Acta Neurol Belg       Date:  2021-04-24       Impact factor: 2.396

6.  Cognitive Impairment of Patient With Neurological Cerebrovascular Disease Using the Artificial Intelligence Technology Guided by MRI.

Authors:  Lifang Zhang; Yanran Li; Lin Bian; Qingrong Luo; Xiaoxi Zhang; Bing Zhao
Journal:  Front Public Health       Date:  2022-03-03

7.  Ginseng Extracts, GS-KG9 and GS-E3D, Prevent Blood-Brain Barrier Disruption and Thereby Inhibit Apoptotic Cell Death of Hippocampal Neurons in Streptozotocin-Induced Diabetic Rats.

Authors:  Jee Youn Lee; Chan Sol Park; Hae Young Choi; Tae Young Yune
Journal:  Nutrients       Date:  2020-08-09       Impact factor: 5.717

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.